Navigation Links
Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
Date:5/20/2013

WOBURN, Mass., May 20, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies.

Prior to joining Flexion, Mr. Driscoll was chief financial officer for Novavax (NASDAQ: NVAX) where he led a team that secured more than $250 million through a combination of investment funding and commercial and government contracts. He was also instrumental in increasing Novavax' institutional shareholder base, expanding analyst coverage and implementing numerous financial reforms that strengthened that company's position. Prior to Novavax, Mr. Driscoll served as chief financial officer and subsequently chief executive officer of publicly-traded Genelabs, chief financial officer of private company Astraris and chief executive officer of OXiGENE.

"We are delighted to add a leader of Fred's experience and expertise to our team as we continue to focus on increasing investor value while advancing our pipeline of sustained release, intra-articular osteoarthritis medicines," said Michael Clayman , M.D., chief executive officer of Flexion. "With Phase 2b data for our lead compound on the horizon, we are confident that Fred will play an important role in the future of the company."

Mr. Driscoll holds a bachelor's degree in accounting and finance from Bentley University in Waltham, Mass.

About Flexion TherapeuticsFlexion is a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal disorders. In our efforts to provide products with superior efficacy and safety,
'/>"/>

SOURCE Flexion Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
6. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
7. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
8. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
9. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
10. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
11. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... (PRWEB) May 21, 2015 Seventh Wave ... safety and efficacy of pharmaceutical products and medical devices, ... Heights, MO 63043, a 50,000 sq. ft. building more ... to enable strategic growth. Facility renovations will begin immediately ... new space will occur in September. , “We ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, ... (FPWR), a nonprofit organization dedicated to supporting research ... syndrome (PWS), announced today that FPWR has received ... Irina Shaulov contributed $1 million in ... initiatives.  "Our ...
(Date:5/21/2015)... 2015 uBiome, the leading startup ... with PicnicHealth, a healthcare company that collects and ... Inflammatory Bowel Disease (IBD) will receive a complementary ... research kit. Both companies were funded by Y ... For more information on this partnership and how ...
(Date:5/21/2015)... -- Imagine being able to probe and ... others. Being able to read faces and enjoy genuine ... anticipate their thoughts and actions like never before. Use ... create unique abstract paintings and video, or, play a ... first-person-shooter as it creates action, dialog, and outcomes based ...
Breaking Biology Technology:Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 35 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2
... 22 Techne Corporation,s,(Nasdaq: TECH ) consolidated net ... to $28.6 million or $.74 per diluted share,compared with ... quarter ended,September 30, 2007. Net earnings as a percentage ... of last year to 41.2% for the quarter ended,September ...
... Inc.,(Nasdaq: MDVN ) today announced that the ... its collaboration with,Pfizer Inc. expired on October 20, ... to jointly develop and commercialize,Dimebon for the treatment ... waiting period triggers an up-front payment to Medivation,of ...
... ,silent killers, such as ... Screenings provide potentially life-saving data, including actual images ... and their doctors ... Oct. 22 HealthYes!(TM), based in Austin,is a premier ...
Cached Biology Technology:Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 5Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer 2HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 2HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 3HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 4HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 5HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 6HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 7
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... (March 14, 2012) A research team has identified ... in gene expression, within reprogrammed skin cells. These signatures ... reprogrammed skin cells or induced pluripotent stem cells (iPSCs), ... how the expression of the protein is controlled brings ...
... A new research survey conducted by the Center for ... Center shows the Bangladeshi community in New York City experiences ... and lack of diabetes awareness. The study, published in the ... Health , also found the Bangladeshi community has an interest ...
... Scientists at Johannes Gutenberg University Mainz (JGU) in ... proteins. Detailed knowledge of the dynamics of proteins is ... that occur on the molecular level. To date, this ... with fluorescent substances, but unfortunately this changes the proteins ...
Cached Biology News:Epigenetic signatures direct the repair potential of reprogrammed cells 2New study shines light on barriers to diabetes care in NYC Bangladeshi community 2Gold nanoantennas detect proteins 2
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
...
...
Biology Products: